US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate.

ABSTRACT:

Importance

Market exclusivity for daily injections of glatiramer acetate, a disease-modifying therapy for multiple sclerosis, expired in 2015. In 2014, the manufacturer launched an alternate 3-times-weekly version that was widely adopted, sustaining market dominance of brand-name glatiramer until late 2017.

Objective

To estimate excess US spending associated with the transition from daily to 3-times-weekly glatiramer.

Design, setting, and participants

This economic evaluation estimated total US glatiramer spending from January 1, 2011, to June 30, 2019, using a national cohort from 3 data sources that collectively represent approximately 40% of the US glatiramer market: Medicare Part D, Medicaid, and a claims database of commercially insured and Medicare Advantage pat

SUBMITTER: Rome BN 

PROVIDER: S-EPMC7372513 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature